Hypertensive Renal Disease

• Mechanical injury and endothelial dysfunction: Sustained elevations in systemic blood pressure are transmitted to the glomerular microcirculation, causing increased intraglomerular pressure (increased Pgh). This mechanical stress triggers endothelial injury, manifesting as loss of the endothelial glycocalyx, increased vascular permeability, and reduced nitric oxide (NO) bioavailability. The resultant endothelial dysfunction perpetuates the hypertensive state through reduced NO-mediated vasodilation and increased vasoconstrictive tone.

• Renin-angiotensin-aldosterone system (RAAS) activation and glomerular hyperfiltration: Chronic hypertension activates the intrarenal RAAS, promoting angiotensin II (Ang II) generation within glomerular cells. Ang II causes preferential efferent arteriolar vasoconstriction via AT1 receptors, amplifying intraglomerular pressure and initiating a cycle of glomerular hyperfiltration. While acutely enhancing GFR, sustained hyperfiltration causes progressive glomerular injury through podocyte stress and increased proteinuria.

• Podocyte injury and glomerulosclerosis: Mechanical stress and Ang II-mediated signaling trigger podocyte apoptosis, loss of the slit diaphragm (containing nephrin, podocin, and alpha-actinin-4), and foot process effacement. This leads to proteinuria, which further perpetuates injury via direct tubular toxicity and activation of inflammatory pathways. Progressive podocyte loss is irreversible, resulting in glomerular collapse and focal segmental glomerulosclerosis (FSGS) pattern histologically.

• Tubulointerstitial inflammation and fibrosis: Hypertensive injury extends beyond glomeruli to induce tubular atrophy and interstitial fibrosis. Ang II promotes transforming growth factor-beta (TGF-β) signaling, driving myofibroblast differentiation and excessive collagen deposition. Oxidative stress from NADPH oxidase activation generates reactive oxygen species (ROS), exacerbating inflammation and perpetuating the fibrotic cascade.

• Arterial and arteriolar remodeling: Chronic hypertension triggers vascular smooth muscle cell proliferation and hypertrophy in both afferent and efferent arterioles, creating "arterial stiffness" and reducing autoregulation capacity. Hyaline arteriolosclerosis (homogeneous deposits of hyaline material in arteriolar walls) is the pathologic hallmark and correlates with disease severity.

• Loss of renal autoregulation: Normal kidneys maintain constant GFR across a wide range of systemic blood pressures (80-180 mmHg) through myogenic and tubuloglomerular feedback mechanisms. Chronic hypertension impairs these adaptive mechanisms, causing GFR to become pressure-dependent, so further elevations in systemic BP directly amplify glomerular injury.

• Essential (primary) hypertension: Accounts for >90% of hypertensive renal disease cases. Multiple genetic polymorphisms affecting sodium handling, RAAS function, and endothelial-derived factors predispose to both hypertension development and renal vulnerability.

• Secondary hypertension: Renovascular disease, primary aldosteronism, pheochromocytoma, and obstructive sleep apnea must be excluded to confirm hypertensive nephrosclerosis as the primary cause.

• African American ancestry: Confers 3-4 fold higher risk of ESRD from hypertension; genetic factors include variants in the APOL1 gene (apolipoprotein L1), which increase glomerular injury susceptibility and are carried at higher frequencies in African populations.

• Male sex: Men develop hypertensive ESRD at approximately 2:1 ratio compared to women, likely due to loss of estrogen-mediated renoprotection in postmenopausal women (though postmenopausal women eventually approach male rates).

• Degree and duration of hypertension: Blood pressure elevation >160/100 mmHg confers significantly higher risk; cumulative exposure duration matters more than current BP alone.

• Concurrent diabetes mellitus: Hypertension accelerates diabetic nephropathy progression synergistically; coexistence dramatically increases ESRD risk.

• Obesity and metabolic syndrome: Associated with activation of the RAAS, sympathetic nervous system, and oxidative stress; increases glomerular hyperfiltration.

• Low birth weight and reduced nephron number: Impaired nephrogenesis increases susceptibility to hypertensive injury through reduced renal reserve.

• Smoking: Accelerates renal disease progression through oxidative stress and endothelial dysfunction.

• Hyperlipidemia: Glomerular lipid deposition and oxidative modification promote proteinuria and glomerulosclerosis.

• Asymptomatic renal dysfunction: Most common presentation; renal disease discovered through elevated serum creatinine or reduced eGFR on routine laboratory studies. Patients may have had undiagnosed or inadequately controlled hypertension for years prior.

• Microalbuminuria and proteinuria: Often precedes significant eGFR decline; albuminuria >30 mg/day indicates early glomerular injury and is a strong independent cardiovascular risk marker. Nephrotic-range proteinuria (>3.5 g/day) is less common in pure hypertensive disease and should prompt investigation for superimposed or alternative glomerular disease.

• Hypertension on physical examination: May be absent, mild, or severe depending on disease stage and antihypertensive medication compliance. Systolic and/or diastolic elevation may be the only objective finding.

• Left ventricular hypertrophy (LVH): Present in approximately 50% of patients with hypertensive renal disease; detected by physical examination (sustained apical impulse, S4 gallop) or electrocardiography (Sokolow-Lyon or Cornell criteria). LVH reflects parallel development of hypertensive cardiac injury.

• Retinal findings: Hypertensive retinopathy may range from minimal arteriolar narrowing (grade I) to papilledema and flame hemorrhages (grade IV), with higher grades correlating with more severe renal disease and increased cardiovascular risk.

• Edema: Absent in early disease; peripheral edema may develop with progression to ESRD and fluid retention. Pulmonary edema may occur if hypertensive crisis precipitates acute decompensated heart failure.

• Symptoms of uremia: In advanced CKD (eGFR <15 mL/min/1.73m²), patients may develop nausea, fatigue, pruritus, and anorexia.

• Hypertensive urgency/emergency presentation: Rarely, patients present with malignant hypertension, characterized by acute, severe hypertension (typically BP >180/120 mmHg) with evidence of end-organ injury (acute kidney injury, encephalopathy, myocardial infarction).

• Serum creatinine and estimated GFR (eGFR): Elevated creatinine with proportionate decline in eGFR (calculated via CKD-EPI equation) establishes renal dysfunction. eGFR <60 mL/min/1.73m² indicates CKD. Progressive decline in eGFR despite adequate blood pressure control is expected with established hypertensive nephrosclerosis.

• Urinalysis and urine albumin-to-creatinine ratio (UACR): Dipstick proteinuria or positive protein on urinalysis should be quantified via UACR. UACR 30-300 mg/g indicates microalbuminuria (early marker of glomerular injury); UACR >300 mg/g indicates macroalbuminuria. Hematuria is absent or minimal in pure hypertensive disease; hematuria (especially RBC casts) suggests alternative glomerular pathology.

• Electrolytes and renal function panel: Potassium and bicarbonate inform baseline status and guide subsequent antihypertensive medication selection. Elevated potassium may develop with progression to stage 4-5 CKD, limiting use of RAAS inhibitors.

• Blood pressure measurement and documentation: Diagnosis of hypertension requires sustained BP elevation typically on multiple occasions; out-of-office BP measurement (home monitoring, ambulatory BP monitoring) may be helpful to exclude white coat hypertension or confirm resistant hypertension.

• Exclusion of secondary hypertension: When hypertension onset is <30 years old, BP is resistant to 3+ medications, or clinical features suggest secondary causes, screening for renovascular disease (captopril renal scintigraphy, renal artery duplex ultrasound, or CT angiography), primary aldosteronism (aldosterone:renin ratio), pheochromocytoma (24-hour urine metanephrines), and hyperthyroidism (TSH) is warranted.

• Renal ultrasonography: Normal to bilaterally symmetrical, small kidneys (<9 cm long) with increased echogenicity support chronic hypertensive nephrosclerosis. Asymmetric kidney size raises concern for unilateral renal artery stenosis. Absence of hydronephrosis excludes obstruction.

• Renal artery imaging: Indicated only if clinical suspicion for renovascular disease exists (severe/resistant hypertension, acute AKI with RAAS inhibitor initiation, unilateral kidney size asymmetry). Doppler ultrasound, CTA, or MRA may demonstrate stenotic lesions.

• Kidney biopsy: Rarely performed for diagnostic confirmation; reserved for atypical presentations (heavy proteinuria, hematuria, rapid GFR decline, young age with hypertension) to exclude primary glomerulonephritis. Histology shows hyaline arteriolosclerosis, arteriolar narrowing, glomerular collapse with FSGS pattern, and tubulointerstitial fibrosis.

• Electrocardiography and echocardiography: ECG may demonstrate LVH (Sokolow-Lyon or Cornell voltage criteria, repolarization abnormalities). Echocardiography quantifies LV mass, assesses systolic and diastolic function, and may reveal concentric LV remodeling.

• Diagnostic criteria (exclusionary): Hypertensive nephrosclerosis is diagnosed when (1) sustained hypertension is present, (2) renal dysfunction exists with appropriate imaging (small, echogenic kidneys), (3) proteinuria is absent or modest (<3.5 g/day), and (4) primary renal disease and secondary hypertension are excluded.

• Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs): First-line agents for hypertensive renal disease with proteinuria or albuminuria. These drugs preferentially dilate the efferent arteriole, reducing intraglomerular pressure and proteinuria independent of systemic BP reduction. Lisinopril, enalapril, losartan, valsartan, irbesartan are commonly used. ACEi/ARBs provide additional renal protection beyond BP lowering and reduce cardiovascular events. Initial acute rise in creatinine (up to 30%) is expected and usually stabilizes; exceeding 30% decline warrants evaluation for renal artery stenosis. ARBs are preferred in ACEi-intolerant patients (persistent cough occurs in 10-20% of ACEi users). Dual therapy with ACEi + ARB is not recommended due to increased hyperkalemia and renal dysfunction risk without added benefit.

• Calcium channel blockers (CCBs): Second-line agents, particularly effective in African Americans and elderly patients. Amlodipine, diltiazem, verapamil reduce BP and improve cardiovascular outcomes. Non-dihydropyridine CCBs (diltiazem, verapamil) may have modest antiproteinuric effects. CCBs do not elevate potassium and may be combined with ACEi/ARBs. Dihydropyridine CCBs may slightly increase proteinuria; non-dihydropyridines are preferred in proteinuric patients.

• Thiazide and thiazide-like diuretics: Second-line agents for hypertension management. Hydrochlorothiazide, chlorthalidone, indapamide effectively reduce BP and cardiovascular events. Diuretics should be used cautiously with advanced CKD (eGFR <30 mL/min/1.73m²) where efficacy diminishes; loop diuretics (furosemide) become necessary. Hypokalemia and hyponatremia risk requires monitoring. ACEi/ARB + CCB + diuretic combinations are standard for resistant hypertension.

• Beta-blockers: Reserved for specific indications (post-MI, heart failure with reduced ejection fraction, atrial fibrillation). Not first-line for hypertensive renal disease alone due to less robust renal protection and adverse metabolic effects (hyperglycemia, dyslipidemia).

• Aldosterone antagonists: Spironolactone (potassium-sparing diuretic with antiproteinuric effects) may be considered for resistant hypertension or heart failure coexistence, but requires careful K+ monitoring and is contraindicated if K+ >5.5 mEq/L or eGFR <30 mL/min/1.73m².

• Blood pressure targets: Current guidelines recommend <130/80 mmHg in patients with CKD and hypertension based on SPRINT trial data, though individualization is necessary. For patients with CKD stage 3a-5 with albuminuria, targets may be modestly higher (130-139 mmHg systolic) to avoid hypotension-induced AKI. Gradual BP reduction (over weeks to months) is preferred to avoid acute ischemic events.

• Dietary sodium restriction: Target <2.3 g/day (approximately <100 mEq/day); reduces BP 5-10 mmHg, enhances antihypertensive medication efficacy, and reduces proteinuria. Greater benefit in salt-sensitive individuals (African Americans, elderly, CKD patients).

• Weight reduction: Aim for BMI 18.5-24.9 kg/m²; each 1 kg weight loss reduces BP approximately 1 mmHg. Particularly effective in overweight/obese patients.

• Alcohol moderation: Limit to ≤2 drinks/day in men, ≤1 drink/day in women; reduces BP and cardiovascular risk.

• DASH diet and potassium supplementation: DASH (Dietary Approaches to Stop Hypertension) diet emphasizing fruits, vegetables, whole grains, and low-fat dairy products reduces BP 8-14 mmHg. Potassium supplementation is contraindicated with ACEi/ARB use or advanced CKD due to hyperkalemia risk.

• Physical activity: Moderate-intensity aerobic exercise 150 minutes/week reduces BP 5-8 mmHg and improves cardiovascular fitness.

• Smoking cessation: Eliminates acute BP elevation and accelerated renal disease progression.

• Monitoring parameters: Serum creatinine and eGFR should be reassessed 1-2 weeks after initiating/adjusting ACEi/ARB (expect creatinine rise <30%), then every 6-12 months with stable renal function. Potassium, bicarbonate, and proteinuria should be monitored

Complications of the disease

• Progression to ESRD: Nephron loss triggers compensatory hyperfiltration in remaining glomeruli, which accelerates sclerosis — a self-perpetuating cycle. Signals: sustained eGFR decline and rising albuminuria despite BP control; hypertension is the second leading cause of ESRD in the US after diabetes.
• Hyperkalemia and metabolic acidosis: Reduced distal potassium secretion and impaired ammoniagenesis/net acid excretion. Signals: peaked T waves and widened QRS (a rhythm-threatening emergency — calcium gluconate first for membrane stabilization), low serum bicarbonate. KDIGO recommends treating metabolic acidosis in CKD, as it drives muscle catabolism and bone loss.
• CKD–mineral and bone disorder: Falling calcitriol and phosphate retention drive secondary hyperparathyroidism. Signals: high phosphate, high PTH, low/normal calcium, vascular calcification.
• Anemia of CKD: Deficient peritubular fibroblast erythropoietin production plus hepcidin-mediated iron sequestration. Signal: normocytic, normochromic anemia; evaluate iron stores before ESA therapy per KDIGO.
• Accelerated cardiovascular disease: LVH, heart failure (frequently HFpEF), and sudden death; albuminuria itself is an independent risk marker. Volume overload causing flash pulmonary edema is an emergency.
• Malignant hypertension with thrombotic microangiopathy: Fibrinoid necrosis and onion-skin hyperplastic arteriolosclerosis produce mechanical RBC shearing. Signals: schistocytes, thrombocytopenia, rising creatinine, papilledema — a hypertensive emergency requiring IV titratable therapy.
• Uremic complications: Pericarditis (friction rub, an emergency indication for urgent dialysis), encephalopathy, and bleeding from platelet dysfunction.

Complications of treatment

• RAAS-inhibitor AKI: Loss of angiotensin II–mediated efferent tone drops filtration pressure. A creatinine rise beyond roughly 30% suggests bilateral renal artery stenosis or volume depletion — investigate rather than reflexively continuing.
• ACEi angioedema: Bradykinin accumulation; airway involvement is an emergency. Switching to an ARB is generally acceptable but requires counseling.
• Fetal toxicity: ACEi/ARBs cause fetal renal failure and oligohydramnios; contraindicated in pregnancy — captopril included, despite its usefulness for rapid titration outside pregnancy.
• Diuretic effects: Thiazides cause hyponatremia, hypokalemia, and hyperuricemia/gout; spironolactone causes hyperkalemia and gynecomastia.
• Overly rapid BP lowering: Autoregulation is rightward-shifted, so abrupt normalization causes watershed cerebral or renal ischemia.

• The two histologic buzzwords are not interchangeable: Hyaline arteriolosclerosis (homogeneous pink protein deposits in arteriolar walls) is benign/chronic nephrosclerosis; hyperplastic "onion-skin" arteriolosclerosis with fibrinoid necrosis is malignant hypertension. Diabetes also causes hyaline arteriolosclerosis — but classically of both afferent and efferent arterioles.
• The imaging signature: bilaterally small, symmetric, echogenic kidneys. Asymmetric kidneys are the examiner's cue for unilateral renal artery stenosis, not hypertensive nephrosclerosis.
• The single association most tested: APOL1 risk variants in patients of West African ancestry, explaining the disproportionate rate of hypertension-attributed ESRD and the FSGS-like collapsing pattern on biopsy.
• Best next step when albuminuria is found: confirm with a repeat urine albumin-to-creatinine ratio and start (or maximize) an ACE inhibitor or ARB — never both together. Recheck creatinine and potassium in 1–2 weeks.
• Do not stop the ACEi for a modest creatinine bump. A rise up to about 30% reflects the intended fall in intraglomerular pressure and is renoprotective, not nephrotoxic. A larger or progressive rise points to bilateral renal artery stenosis or hypovolemia.
• Trial anchor: AASK showed an ACE inhibitor slowed progression of hypertensive kidney disease in African American patients better than amlodipine or a beta blocker — the classic distractor is choosing a dihydropyridine CCB "because it works better in Black patients," which applies to BP lowering in the absence of albuminuria (ACC/AHA 2017), not to proteinuric CKD.
• BP target: ACC/AHA 2017 says <130/80 mm Hg in CKD; KDIGO 2021 goes further, suggesting a systolic target below 120 mm Hg using standardized office measurement. Know that the two bodies differ and that KDIGO's number is inseparable from the measurement technique.
• Red flags that argue against the diagnosis: nephrotic-range proteinuria, dysmorphic RBCs or RBC casts, rapid GFR decline, or young age at onset. These demand a workup for glomerulonephritis or secondary hypertension — hypertensive nephrosclerosis remains a diagnosis of exclusion.